HTR2A and metabolic dysfunction-associated steatotic liver disease: As neural blockade and HTR2A antagonists suppress this pathology, it is possible that 5-HT and its specific receptor-mediated signaling in a tissue represent novel therapeutic options for treating palatable food-induced NAFLD.